NCT05210101 - A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions

SARS CoV 2 Infection

Interventions

DRUG

Sotrovimab

Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston